Mana.bio, a biotechnology company revolutionizing targeted RNA delivery through AI-enabled lipid nanoparticle (LNP) discovery ...

WuXi AppTec, a leading global contract research, development, and manufacturing organization (CRDMO) presented 13 scientific posters at the 2026 Annual Meeting of the American Association for Cancer ...

Mirai Bio to Unveil Two Next Generation Programs for Targeted Nucleic Acid Delivery Beyond the Liver at ASGCT 2026 ...

Most lipid nanoparticle (LNP) platforms face the same constraint: they are cleared rapidly by the liver, which makes it hard ...

Lipid nanoparticles (LNPs) have emerged as a transformative platform in the field of neurotherapeutics, particularly for targeting the aging brain.

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...

Next-generation cell therapies are reshaping therapeutics by precisely engineering living cells for both ex vivo and in vivo applications. Cutting-edge tools—including Cas enzymes (Cas9, Cas12a), base ...

(RTTNews) - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Merck KGaA (MKKGY, MRCG.DE, MRK.MI) announced that they have entered into an evaluation and option agreement to advance the development ...